TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 vs. 24 Weeks in Patients with HER2-positive Breast Cancer
- Rimawi, Mothaffar F
- Niravath, Polly
- Wang, Tao
- Rexer, Brent N
- Forero, Andres
- Wolff, Antonio C
- Nanda, Rita
- Storniolo, Anna M
- Krop, Ian
- Goetz, Matthew P
- Nangia, Julie R
- Jiralerspong, Sao
- Pavlick, Anne
- Veeraraghavan, Jamunarani
- De Angelis, Carmine
- Gutierrez, Carolina
- Schiff, Rachel
- Hilsenbeck, Susan G
- Osborne, Charles Kent
Publication date
January 2020
DOI Publisher
American Association for Cancer Research (AACR)Abstract
Prior neoadjuvant trials with 12 weeks of dual anti-HER2 therapy without chemotherapy demonstrated a meaningful pathologic complete response (pCR) in patients with HER2-positive breast cancer. In this trial, we sought to determine whether longer treatment would increase the rate of pCR
Add to ORKG